logo-loader
viewElixir Energy Ltd

Elixir Petroleum farming out North Sea oil permit

au_uk_map350_50c56c6fa556b.jpg

Elixir Petroleum (ASX: EXR) has reached an agreement to farm out a stake in its UK North Sea permit to Adriatic Oil.

Adriatic will be assigned a 25% participating interest in Seaward Production Licence P1921 by funding the cost of interpreting newly purchased 3D seismic data over the area up to an agreed maximum value and a cash consideration towards Elixir’s past costs.

If interpretation of the 3D data indicates that reprocessing is required, Adriatic will have an option to earn an additional 25% participating interest by carrying Elixir’s share of the costs on a partially promoted basis.

If the 3D data does not require reprocessing and a drill ready target exists, Adriatic will have an option to acquire an additional 25% participating interest by paying £100,000 and granting a 10% gross overriding royalty to Elixir.

P19212 contains the large Sunset stratigraphic oil prospect in the Middle Jurassic Beatrice Formation.

Sunset is predicted to have Beatrice Formation reservoir sands, which have been identified as an acoustic impedance anomaly on several 2D seismic lines.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Elixir Energy Ltd

Price: 0.033 AUD

ASX:EXR
Market: ASX
Market Cap: $16.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical sees 'potentially quicker route to market' for its erectile...

Futura Medical PLC's (LON:FUM) executive director and head of R&D Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel. James says while MED2005 showed strong efficacy, excellent safety and rapid speed...

48 minutes ago

2 min read